Jump to content

Drilldown: Medicines

Pharmacopedia
BrowseCategoriesLog in
Pharmacopedia is being built in public. Pages may be incomplete.About this site

Choose a table:


Medicines > classes : Anti-CGRP ligand monoclonal antibody or Botanical or Opioid

Use the filters below to narrow your results.

generic:
None (3) · Codeine (2)
brand:
None (32) · (multiple, generic dominant) (1) · Ajovy (1) · Alfenta (1) · Darvon (1) · Demerol (1) · Dilaudid (1) · Duragesic (1) · Emgality (1) · Heroin (1) · Krokodil (1) · Nubain (1) · Nucynta (1) · O-DSMT (1) · Opana (1) · Stablon (1) · Stadol (1) · Sufenta (1) · Talwin (1) · Ultiva (1) · Vicodin (1) · Vyepti (1)
classes: (Click arrow to add another value)
mechanism:
Potent mu-opioid receptor agonist (6) · Mu-opioid receptor agonist (4) · Contains LSA (2) · Contains mescaline (2)
uses:
None (49) · Mild to moderate pain; cough suppression (low-dose). (1) · Preventive treatment of migraine in adults (1) · Preventive treatment of migraine in adults (episodic and chronic) (1) · Preventive treatment of migraine in adults; episodic cluster headache (1)
starting dose:
None (49) · 100 mg IV every 3 months; may increase to 300 mg IV every 3 months (1) · 225 mg SC monthly, or 675 mg SC every 3 months (quarterly) (1) · Adult: 15–60 mg every 4 hours as needed. (1) · Migraine: 240 mg SC loading dose, then 120 mg SC monthly. Cluster: 300 mg SC at onset of cluster period, then monthly during cluster. (1)
preparations:
None (49) · 100 mg/mL vial for IV infusion (1) · 120 mg/mL prefilled syringe or autoinjector (1) · 225 mg/1.5 mL prefilled syringe or autoinjector (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)
fda max:
None (49) · 240 mg loading + 120 mg/month for migraine; 300 mg/month for cluster (1) · 300 mg/quarter (1) · 360 mg/day (1) · 675 mg/quarter (1)
routes:
None (49) · Intravenous infusion (1) · PO (only formulation marketed in the US). (1) · Subcutaneous (2)
onset:
None (49) · 30–60 min (PO) (1) · Effect demonstrated within 24 hours in some patients (1) · Over weeks (2)
duration:
None (49) · 3-month dosing interval (1) · 4–6 hours (1) · Monthly dosing (1) · Monthly or quarterly dosing (1)
halflife:
None (49) · 2.5–3 hours (1) · ~27 days (2) · ~31 days (1)
bioavailability:
None (49) · 100% (IV) (1) · Not formally established (1) · Not formally established (high SC) (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)
pregnancy:
None (49) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Limited data; avoid (3)
legal:
None (49) · Rx (3) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1)

Showing below up to 56 results in range #1 to #56.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"